Recombinant DNA Technology Market Growth Statistics, Sales Projection, Business Opportunities and Outlook by 2027

Market overview for recombinant DNA technology

The recombinant DNA technology market is expected to reach a CAGR of 6.9% of the CAGR during the forecast period. Recombinant DNA technology is used to genetically modify organisms and products to survive in harsh conditions and achieve high productivity.

This technology has tremendous applications in various industries. It is mainly used in specific areas of genomics, applied immunology, pharmaceutical therapeutics, and diagnostic tools. These applications and their growing research and development activities are driving the growth of the Recombinant DNA Technology Market.

The key growth factors such as increasing adoption of genetically modified crops and adoption of recombinant DNA technology in biopharmaceuticals are mainly driving the market. Other growth drivers are the demand for effective therapeutic treatments of diseases and stronger growth of the biopharmaceutical pipeline, as well as the increasing demands to improve the production of recombinant proteins.

Request a free sample at:

During the COVID-19 pandemic, the recombinant DNA technology market has experienced a drop in productivity and revenue due to the lockdown. But after the government got permission to sell essential items, the demand of the market started to increase and kept its growth constancy.

As a result of the industrial player’s efforts and marketing strategies, the Recombinant DNA Technology market will emerge with various growth opportunities.

Recombinant DNA Technology Market Segmentation

The recombinant DNA technology market is segmented into various segments such as product, components, application and end-user.

The product segment of the market is divided into non-medical, medical and other. The non-medical segment is divided into specialty chemicals, biotech crops and others, while the medical segment is divided into therapeutics, human proteins and vaccines.

The component segment is fragmented into a cloning vector and an expression system. The cloning vector is further subfragmented into cosmid, plasmid, phage, yeast artificial chromosome (YAC), human artificial chromosome (HAC) and bacterial artificial chromosome (BAC). The segment of the expression system is also subfragmented into bacteria, baculovirus or insect, mammalian, yeast and others.

The scope of the market is segmented into Food & Agriculture, Health & Disease Environment, and Others.

The health and disease segment will take the highest market share of the recombinant DNA technology market due to the increasing number of chronic diseases and the presence of a wide range of recombinant products to treat human diseases such as vaccines, drugs, etc.

The end-user segment of the market is fragmented into pharmaceuticals, biotechnology companies, academic and government research institutes, and others.

Regional Analysis of the Recombinant DNA Technology Market

The geographic report of Recombinant DNA Technology Market shows the regions covered like Europe, Americas, Middle East & Africa and Asia Pacific.

Among these, America will feature prominently due to the tremendous applications of recombinant DNA techniques for the development of genetic veterinary products, the development of modified crops, gene therapy, and the production of biopesticides and biofuels.

The European recombinant DNA technology market will be the second largest region in terms of shares during the forecast period due to rising government investments and high-quality hospital facilities. Other factors driving the regional market include low-cost sequencing, collaborations and partnerships, and increasing demand from research labs.

Browse the detailed table of contents with the COVID-19 impact analysis at:

key figures

Top key players in the recombinant DNA technology market are Pfizer Inc. (USA), Sanofi SA (France), Eli Lilly and Company (USA), Biogen Inc. (USA), Biocon Limited (India), Boehringer Ingelheim (Germany ), Amgen Inc. (USA), F. Hoffmann-La Roche Ltd (Switzerland), Profacgen (USA), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Genscript Biotech (USA), Merck & Co. , Inc (US), Cibus (US), GlaxoSmithKline plc (UK), New England Biolabs (US), Horizon Discovery Group PLC (US), Monsanto Company (US).

News from the recombinant DNA technology industry

In 2017, Novatris AG received FDA approval for its gene transfer-based product for acute lymphoblastic leukemia.

Browse related reports at:

Cosmetic dentistry market Research Report – Forecast to 2027

Structural Cardiac Devices Market Research Report – Forecast to 2027

Blockchain technology in the healthcare market Research Report – Forecast to 2027

About market research future:

At Market Research Future (MRFR), we enable our clients to unravel the complexities of different industries through our Cooked Research Reports (CRR), Half-Cooked Research Reports (HCRR) and consulting services. The MRFR team’s ultimate goal is to provide our clients with the best quality market research and information services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5th Floor,

New York, New York 10013

United States of America

+1 628 258 0071


Leave a Comment